Embedded Files
DelveInsight’s “Claudin 18.2 directed therapies Target Population, Competitive Landscape, and Market Forecast – 2034” report delivers an in-depth understanding of the Claudin 18.2, historical and forecasted epidemiology as well as the Claudin 18.2 directed therapies market trends in the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan.
Unlock detailed insights into the Claudin 18.2 Directed Therapies Market by downloading the comprehensive report from DelveInsight @ Claudin 18.2 Directed Therapies Therapeutics Market
Key Takeaways from the Claudin 18.2 Directed Therapies Market Report
As per the analysis, Claudin 18.2 expression is observed in gastric, gastroesophageal junction, and pancreatic cancers, making it a selective target for therapy.
According to DelveInsight, the total gastric cancer incident cases including GEJ in the US comprised around 29,500 cases in 2024.
According to the American Cancer Society, gastric cancer is more common in males, with Claudin 18.2-positive cases representing a subset for targeted treatments.
According to the World Health Organization, pancreatic cancer incidence is rising, with Claudin 18.2-directed therapies offering potential for advanced cases.
The leading Claudin 18.2 Directed Therapies Companies such as Astellas, AskGene, Innovent, Antegene, Kelun, AstraZeneca, Phanes, and others.
Promising Claudin 18.2 Directed Therapies such as VYLOY (zolbetuximab), ASKB589, IBI-343, AZD0901, ATG022, SKB315, Spevatamig (PT886), and others.
Gain a competitive edge in the Claudin 18.2 Directed Therapies Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Claudin 18.2 Directed Therapies Treatment Drugs
Claudin 18.2 Directed Therapies Epidemiology Segmentation in the 7MM
Total cases of selected indications for Claudin 18.2 directed therapies
Total eligible patients of the selected indications of Claudin 18.2 directed therapies
Total treated cases in selected indications for Claudin 18.2 directed therapies
Claudin 18.2 Directed Therapies Treatment Market The primary treatment for Claudin 18.2-positive cancers includes chemotherapy, targeted antibodies, and antibody-drug conjugates. Recent advancements include the approval of VYLOY (zolbetuximab) by Astellas in 2024, which enhances treatment options for gastric and GEJ cancers. Focusing on the chronic and severe nature of these cancers, the treatment approach is comprehensive; targeting Claudin 18.2 expression and controlling tumor progression is the key treatment target.
Claudin 18.2 Directed Therapies Market Insights Claudin 18.2 is a serious, life-threatening condition with no cure, serving as a risk factor for numerous complications. While there is no established cure, IHC testing is available to detect expression, and treatment involves monoclonal antibodies and ADCs, alongside chemotherapy. VYLOY, the most innovative targeted treatment, triggers immune-mediated destruction of tumor cells.
Discover key developments and opportunities in the Claudin 18.2 Directed Therapies Market. Click here to learn more from DelveInsight's latest report @ Claudin 18.2 Directed Therapies Market Size
Claudin 18.2 Directed Therapies Marketed Drugs
VYLOY (zolbetuximab): Astellas In October 2024, the US Food and Drug Administration approved VYLOY (zolbetuximab) for use in combination with fluoropyrimidine- and platinum-based chemotherapy as a first-line treatment for adults with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors are Claudin 18.2-positive. VYLOY is the first Claudin 18.2-directed cytolytic antibody approved for use in the United States that triggers immune-mediated tumor cell destruction.
ASKB589: AskGene In Phase III trials, ASKB589 is a humanized IgG1 monoclonal antibody targeting CLDN18.2, showing good safety and tolerability in combination with CAPOX and PD-1 inhibitors for G/GEJ cancer.
Claudin 18.2 Directed Therapies Emerging Drugs
IBI-343 - Innovent IBI-343 is a recombinant human monoclonal antibody directed against Claudin 18.2, conjugated to topoisomerase I inhibitor payload (Exatecan). The drug has received Fast Track Designation from the U.S. FDA and is currently being evaluated in the Phase III G-HOPE trial.
AZD0901 - AstraZeneca AZD0901 is an antibody-drug conjugate targeting Claudin 18.2, in Phase III trials for GC/GEJ and solid tumors, showing potential in advanced cancers.
Other novel emerging drugs in the Claudin 18.2 Directed Therapies treatment market in different clinical trial phases include - ATG022/ATN022: Antegene/Antennova, SKB315: Kelun, Spevatamig (PT886): Phanes, and others.
Claudin 18.2 Directed Therapies Market Outlook The Claudin 18.2 Directed Therapies Market is a competitive landscape with targeted therapies entering the market. The oncology drugs market is moderately fragmented, with significant players launching novel antibodies and ADCs. The market competitors are developing not only novel therapies but also diagnostic tools for Claudin 18.2 expression. The expansion of the healthcare sector and favorable regulatory support are fueling the growth of the Claudin 18.2 directed therapies market.
Download DelveInsight's Claudin 18.2 Directed Therapies Market report today and stay ahead in this rapidly evolving field. @ Claudin 18.2 Directed Therapies Clinical Trials
Scope of the Claudin 18.2 Directed Therapies Market Report
Coverage- Global
Study Period- 2020-2034
Claudin 18.2 Directed Therapies Companies- Astellas, AskGene, Innovent, Antegene, Kelun, AstraZeneca, Phanes, and others.
Claudin 18.2 Directed Therapies Therapies- VYLOY (zolbetuximab), ASKB589, IBI-343, AZD0901, ATG022, SKB315, Spevatamig (PT886), and others.
Claudin 18.2 Directed Therapies Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Claudin 18.2 Directed Therapies Unmet Needs, KOL's views, Analyst's views, Claudin 18.2 Directed Therapies Market Access and Reimbursement
Download the report to understand which factors are driving Claudin 18.2 Directed Therapies Market Trends @ Claudin 18.2 Directed Therapies Market Trends
Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary of Claudin 18.2 Directed Therapies
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Claudin 18.2 Directed Therapies Market Overview at a Glance in the 7MM
7 Claudin 18.2 Directed Therapies: Background and Overview
8 Claudin 18.2 Directed Therapies Treatment and Management
9 Target Patient Pool
10 Claudin 18.2 Directed Therapies Marketed Therapies
11 Claudin 18.2 Directed Therapies Emerging Therapies
12 Claudin 18.2 Directed Therapies: Seven Major Market Analysis
13 SWOT Analysis of Claudin 18.2 Directed Therapies
14 KOL Views of Claudin 18.2 Directed Therapies
15 Unmet Needs of Claudin 18.2 Directed Therapies
16 Market Access and Reimbursement
17 Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
Page updated
Google Sites
Report abuse